KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Change in Accured Expenses (2016 - 2025)

Travere Therapeutics (TVTX) has disclosed Change in Accured Expenses for 15 consecutive years, with $6.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Accured Expenses fell 74.21% year-over-year to $6.2 million, compared with a TTM value of -$85000.0 through Dec 2025, down 101.51%, and an annual FY2025 reading of -$85000.0, down 101.51% over the prior year.
  • Change in Accured Expenses was $6.2 million for Q4 2025 at Travere Therapeutics, up from -$7.9 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $24.2 million in Q4 2024 and bottomed at -$62.6 million in Q2 2024.
  • Average Change in Accured Expenses over 5 years is $2.5 million, with a median of $4.2 million recorded in 2022.
  • Peak annual rise in Change in Accured Expenses hit 9122.69% in 2024, while the deepest fall reached 1865.17% in 2024.
  • Year by year, Change in Accured Expenses stood at $21.0 million in 2021, then tumbled by 80.13% to $4.2 million in 2022, then skyrocketed by 314.35% to $17.3 million in 2023, then soared by 40.03% to $24.2 million in 2024, then tumbled by 74.21% to $6.2 million in 2025.
  • Business Quant data shows Change in Accured Expenses for TVTX at $6.2 million in Q4 2025, -$7.9 million in Q3 2025, and $9.8 million in Q2 2025.